Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03720990 · ClinicalTrials.gov registry record · Phase 1
Smith-Lemli-Opitz Syndrome and Cholic Acid
A Phase 1 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03720990 is a Phase 1 study that has completed, run by University of Nebraska. The registered enrollment target is 12 participants.
The verdict
NCT03720990, a Phase 1 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether dietary cholic acid therapy benefits people with Smith-Lemli-Opitz syndrome (SLOS) by leading to an increase in plasma cholesterol and reduction in harmful cholesterol precursors. SLOS participants will be treated with dietary cholic acid for 8 weeks and plasma cholesterol and cholesterol precursor metabolites will be measured.
Interventions
- DRUG Cholic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-03-27 |
| Est. Completion | 2023-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03720990
The ClinicalTrials.gov registry entry for NCT03720990 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cholic Acid is the first listed.
NCT03720990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03720990 about?
NCT03720990 is a clinical study titled "Smith-Lemli-Opitz Syndrome and Cholic Acid". The purpose of this study is to determine whether dietary cholic acid therapy benefits people with Smith-Lemli-Opitz syndrome (SLOS) by leading to an increase in plasma cholesterol and reduction in harmful cholesterol precursors. SLOS participants will be treated with dietary cholic acid for 8 weeks...
What is the current status of trial NCT03720990?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-03-27. Estimated completion is 2023-09-30.
What interventions are being tested in trial NCT03720990?
The interventions under investigation include: Cholic Acid (DRUG).
Who is sponsoring clinical trial NCT03720990?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.